Age (years) |
67 (60-73) |
67 (58 -71.7) |
68 (61 -74) |
0.07 |
White, n (%) |
272 (88.6) |
112 (90.3) |
160 (87.4) |
0.93 |
Male, n (%) |
217 (70.7) |
88 (71) |
129 (70.5) |
0.92 |
Body mass index (kg/m2)
|
29.8 (26.4 -34.2) |
29.7
(26.3 – 34.3) |
29.9 (26.4 -34) |
0.91 |
Duration of AF (years) |
3 (2 – 7) |
3.5 (2–7) |
3 (1.5 –6) |
0.47 |
Duration of amiodarone therapy pre-ablation, years (months) |
5 (3 –
15) |
5 (2.2-13.7) |
6 (3 -16) |
0.42 |
AF type |
|
|
|
0.03 |
Paroxysmal AF, n (%) |
146 (47.6) |
50 (40.3) |
96 (52.5) |
|
Persistent AF, n (%) |
161 (52.4) |
74 (59.7) |
87 (47.5) |
|
Congestive heart failure, n (%) |
74 (24.1) |
34 (27.4) |
40 (21.9) |
0.26 |
Hypertension, n (%) |
207 (67.4) |
80 (64.5) |
127 (69.4) |
0.37 |
Diabetes mellitus, n (%) |
53 (17.3) |
15 (12.1) |
38 (20.8) |
0.04 |
Stroke/TIA, n (%) |
33 (10.7) |
15 (12.1) |
18 (9.8) |
0.53 |
CHA2DS2-VASc score |
2.0 (1.0 -3.0) |
2
(1 – 3) |
2.5 (2 – 4) |
0.18 |
Obstructive sleep apnea, n (%) |
56 (18.2) |
31 (25) |
25 (13.7) |
0.01 |
Chronic kidney disease, n (%) |
42 (13.7) |
17 (13.7) |
25 (13.7) |
0.99 |
Hyperlipidemia, n (%) |
133 (43.3) |
56 (45.2) |
77 (42.1) |
0.59 |
Asthma/COPD, n (%) |
22 (7.2) |
8 (6.5) |
14 (7.7) |
0.68 |
Smoking history, n (%) |
98 (32) |
36 (29) |
62 (34.1) |
0.35 |
ACE inhibitor, n (%) |
77 (25.2) |
35 (28.5) |
42 (23) |
0.27 |
Angiotensin II receptor blocker, n (%) |
65 (21.2) |
24 (19.4) |
41
(22.4) |
0.52 |
Beta blocker/ Calcium channel blocker, n (%) |
251 (81.8) |
107 (86.3) |
144 (78.7) |
0.09 |
Statin, n (%) |
156 (51) |
64 (52) |
92 (50.3) |
0.76 |
Anticoagulation |
|
|
|
0.06 |
None, n (%) |
7 (2.3) |
0 (0) |
7 (3.8) |
|
Coumadin, n (%) |
68 (22.1) |
31 (25) |
37 (20.2) |
|
Direct oral anticoagulant, n (%) |
232 (75.6) |
93 (75) |
139 (76) |
|
LA diameter by TTE (cm) |
4.4 (4.0-5.0) |
4.5 (4.0-5.0) |
4.3 (4.0- 5.0) |
0.73 |
LV ejection fraction by TTE (%) |
55 (50 – 60) |
55 (50 -60) |
55 (50
-60) |
0.64 |